Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The overall goal of this protocol is to:
Evaluate [18F]UCB-2897 as an α-synuclein targeted radiopharmaceutical.
The primary objective is:
• Confirm a specific α -synuclein signal with [18F]UCB-2897 in participants with PD and/or
MSA relative to healthy volunteers
Secondary and exploratory objectives are:
- Determine the safety and tolerability of microdose [18F]UCB-2897
- Evaluate preliminary dosimetry of [18F]UCB-2897
Additional exploratory objectives are:
- Determine the pharmacokinetics / metabolism of [18F]UCB-2897
- Determine the optimal imaging protocol for [18F]UCB-2897